Remegen eyes competitive DMT market as telitacicept shows promise in gMG: GlobalData
With positive Phase III data in AChR+ and MuSK+ gMG, Remegen’s telitacicept enters a crowded DMT space, aiming to stand out…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.